These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

850 related items for PubMed ID: 9776413

  • 1. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.
    Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN.
    J Natl Cancer Inst; 1998 Oct 07; 90(19):1473-9. PubMed ID: 9776413
    [Abstract] [Full Text] [Related]

  • 2. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951.
    Kouwenhoven MC, Gorlia T, Kros JM, Ibdaih A, Brandes AA, Bromberg JE, Mokhtari K, van Duinen SG, Teepen JL, Wesseling P, Vandenbos F, Grisold W, Sipos L, Mirimanoff R, Vecht CJ, Allgeier A, Lacombe D, van den Bent MJ.
    Neuro Oncol; 2009 Dec 07; 11(6):737-46. PubMed ID: 19224764
    [Abstract] [Full Text] [Related]

  • 3. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.
    Ueki K, Nishikawa R, Nakazato Y, Hirose T, Hirato J, Funada N, Fujimaki T, Hojo S, Kubo O, Ide T, Usui M, Ochiai C, Ito S, Takahashi H, Mukasa A, Asai A, Kirino T.
    Clin Cancer Res; 2002 Jan 07; 8(1):196-201. PubMed ID: 11801559
    [Abstract] [Full Text] [Related]

  • 4. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial.
    van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Haaxma-Reiche H, Kros JM, van Kouwenhoven MC, Vecht CJ, Allgeier A, Lacombe D, Gorlia T.
    J Clin Oncol; 2006 Jun 20; 24(18):2715-22. PubMed ID: 16782911
    [Abstract] [Full Text] [Related]

  • 5. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V, Salazar P, Holland EC, Rosenblum MK, Ladanyi M.
    Clin Cancer Res; 2005 Feb 01; 11(3):1119-28. PubMed ID: 15709179
    [Abstract] [Full Text] [Related]

  • 6. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features.
    van den Bent MJ, Looijenga LH, Langenberg K, Dinjens W, Graveland W, Uytdewilligen L, Sillevis Smitt PA, Jenkins RB, Kros JM.
    Cancer; 2003 Mar 01; 97(5):1276-84. PubMed ID: 12599236
    [Abstract] [Full Text] [Related]

  • 7. Loss of heterozygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: relationship to outcome and chemosensitivity.
    Thiessen B, Maguire JA, McNeil K, Huntsman D, Martin MA, Horsman D.
    J Neurooncol; 2003 Sep 01; 64(3):271-8. PubMed ID: 14558604
    [Abstract] [Full Text] [Related]

  • 8. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.
    Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW, Jenkins RB.
    J Clin Oncol; 2000 Feb 01; 18(3):636-45. PubMed ID: 10653879
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Loss of 1p, 19q, and 10q heterozygosity prospectively predicts prognosis of oligodendroglial tumors--towards individualized tumor treatment?
    Ramirez C, Bowman C, Maurage CA, Dubois F, Blond S, Porchet N, Escande F.
    Neuro Oncol; 2010 May 01; 12(5):490-9. PubMed ID: 20156805
    [Abstract] [Full Text] [Related]

  • 11. [Significance and prospects of study on molecular alterations in oligodendrogliomas].
    Gresner SM, Liberski PP.
    Neurol Neurochir Pol; 2007 May 01; 41(4):333-9. PubMed ID: 17874342
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p.
    Hashimoto N, Murakami M, Takahashi Y, Fujimoto M, Inazawa J, Mineura K.
    Cancer; 2003 May 01; 97(9):2254-61. PubMed ID: 12712480
    [Abstract] [Full Text] [Related]

  • 14. Pilot evaluation of 1p and 19q deletions in anaplastic oligodendrogliomas collected by a national cooperative cancer treatment group.
    Jenkins RB, Curran W, Scott CB, Cairncross G.
    Am J Clin Oncol; 2001 Oct 01; 24(5):506-8. PubMed ID: 11586105
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p.
    Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP.
    Am J Pathol; 1994 Nov 01; 145(5):1175-90. PubMed ID: 7977648
    [Abstract] [Full Text] [Related]

  • 17. Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas.
    Fallon KB, Palmer CA, Roth KA, Nabors LB, Wang W, Carpenter M, Banerjee R, Forsyth P, Rich K, Perry A.
    J Neuropathol Exp Neurol; 2004 Apr 01; 63(4):314-22. PubMed ID: 15099021
    [Abstract] [Full Text] [Related]

  • 18. Contribution of 1p, 19q, 9p and 10q Automated Analysis by FISH to the Diagnosis and Prognosis of Oligodendroglial Tumors According to WHO 2016 Guidelines.
    Michaud K, de Tayrac M, D'Astous M, Duval C, Paquet C, Samassekou O, Gould PV, Saikali S.
    PLoS One; 2016 Apr 01; 11(12):e0168728. PubMed ID: 28030632
    [Abstract] [Full Text] [Related]

  • 19. Gene expression profiles associated with treatment response in oligodendrogliomas.
    French PJ, Swagemakers SM, Nagel JH, Kouwenhoven MC, Brouwer E, van der Spek P, Luider TM, Kros JM, van den Bent MJ, Sillevis Smitt PA.
    Cancer Res; 2005 Dec 15; 65(24):11335-44. PubMed ID: 16357140
    [Abstract] [Full Text] [Related]

  • 20. Prognosis of oligodendroglial tumor with ring enhancement showing central necrotic portion.
    Choi KY, Jung TY, Jung S, Kim YH, Moon KS, Kim IY, Kang SS, Lee KH.
    J Neurooncol; 2011 May 15; 103(1):103-10. PubMed ID: 20737192
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.